Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02203825

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells) which recognize NKG2D-ligands on the surface of cancer cells. This study evaluates the safety and feasibility of administering a single intravenous dose of CM-CS1 CAR T-cells to patients with AML, MDS-RAEB and Multiple Myeloma.

Status: 
Recruiting
Study Date: 
Sun, 03/01/2015 to Wed, 03/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Biological: CM-CS1 T-cell infusion Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.